Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 12/20 | 0.84 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045687 | 0.92 | NPY1R (1.00) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL7037686 | 0.91 | NPY1R (0.98) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1593476 | 0.87 | NPY1R (0.82) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1594426 | 0.87 | NPY1R (0.82) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5729134 | 0.87 | NPY1R (0.85) | NPY1RALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1594403 | 0.87 | NPY1R (0.81) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5728933 | 0.86 | NPY1R (0.83) | NPY1RALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1593336 | 0.86 | NPY1R (0.79) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL7491733 | 0.86 | NPY1R (0.82) | NPY1RUSP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL7044284 | 0.85 | NPY1R (0.78) | NPY1RUSP2ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION (US) | 2003-04-10 | — | — | US | claimed |
| EP-1218379-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NPY1R, NPY5R, NPY2R | NPY1R 1/4885USP2 4504/4885ALDH1A1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.